Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Werner Poewe

Showing results (461-470 of 602) with videos related to

Pageof 61
Sort By:
Parkinsonism & Related Disorders|November 12, 2017
MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSPStephanie Mangesius, Anna Hussl, Florian Krismer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 16, 2013
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding studyFabrizio Stocchi, Olivier Rascol, Alain Destee, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 14, 2011
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's diseaseAndrew Lees, Stanley Fahn, Karla M Eggert, et al.
Annals of Clinical and Translational Neurology|February 8, 2020
Cognition in multiple system atrophy: a single-center cohort studySabine Eschlböck, Margarete Delazer, Florian Krismer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 8, 2011
Health-related quality-of-life scales in Parkinson's disease: critique and recommendationsPablo Martinez-Martin, Martine Jeukens-Visser, Kelly E Lyons, et al.
NPJ Parkinson'S Disease|July 15, 2025
Classification of Parkinson's disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilomeCaitlin Walton-Doyle, Beatrice Heim, Eleanor Sinclair, et al.
Brain Stimulation|September 26, 2018
Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trialDoreen Gruber, Martin Südmeyer, Günther Deuschl, et al.
The Lancet. Neurology|September 18, 2010
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]Alex Iranzo, Francisco Lomeña, Heike Stockner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 30, 2025
Advertising to Healthcare Professionals: Insights from Parkinson's Disease in the Movement Disorders JournalAugusto Rachão, António Silva, Luísa Prada, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 18, 2013
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's diseaseRichard Dodel, Bengt Jönsson, Jens Peter Reese, et al.
Pageof 61

Showing results (461-470 of 602) with videos related to

Sort By:
Pageof 61
Parkinsonism & Related Disorders|November 12, 2017
MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSPStephanie Mangesius, Anna Hussl, Florian Krismer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 16, 2013
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding studyFabrizio Stocchi, Olivier Rascol, Alain Destee, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 14, 2011
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's diseaseAndrew Lees, Stanley Fahn, Karla M Eggert, et al.
Annals of Clinical and Translational Neurology|February 8, 2020
Cognition in multiple system atrophy: a single-center cohort studySabine Eschlböck, Margarete Delazer, Florian Krismer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 8, 2011
Health-related quality-of-life scales in Parkinson's disease: critique and recommendationsPablo Martinez-Martin, Martine Jeukens-Visser, Kelly E Lyons, et al.
NPJ Parkinson'S Disease|July 15, 2025
Classification of Parkinson's disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilomeCaitlin Walton-Doyle, Beatrice Heim, Eleanor Sinclair, et al.
Brain Stimulation|September 26, 2018
Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trialDoreen Gruber, Martin Südmeyer, Günther Deuschl, et al.
The Lancet. Neurology|September 18, 2010
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]Alex Iranzo, Francisco Lomeña, Heike Stockner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 30, 2025
Advertising to Healthcare Professionals: Insights from Parkinson's Disease in the Movement Disorders JournalAugusto Rachão, António Silva, Luísa Prada, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 18, 2013
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's diseaseRichard Dodel, Bengt Jönsson, Jens Peter Reese, et al.
Pageof 61